ATE311901T1 - Verwendung von tgf-beta inhibitoren zur behandlung von cerebralen krankheiten - Google Patents

Verwendung von tgf-beta inhibitoren zur behandlung von cerebralen krankheiten

Info

Publication number: ATE311901T1
Authority: AT; Austria
Prior art keywords: tgf; beta inhibitors; cerebral diseases; treat cerebral; compound
Prior art date: 1998-09-03

Application number

AT99946087T

Other languages

English (en)

Inventor

Kerstin Krieglstein

Original Assignee

Bioph Biotech Entw Pharm Gmbh

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

1998-09-03

Filing date

1999-09-01

Publication date

2005-12-15

1999-09-01 Application filed by Bioph Biotech Entw Pharm Gmbh filed Critical Bioph Biotech Entw Pharm Gmbh

2005-12-15 Application granted granted Critical

2005-12-15 Publication of ATE311901T1 publication Critical patent/ATE311901T1/de

Links

ZRKFYGHZFMAOKI-QMGMOQQFSA-N tgfbeta Chemical compound C([C@H](NC(=O)[C@H](C(C)C)NC(=O)CNC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H]([C@@H](C)O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H]([C@@H](C)O)NC(=O)[C@H](CC(C)C)NC(=O)CNC(=O)[C@H](C)NC(=O)[C@H](CO)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@@H](NC(=O)[C@H](C)NC(=O)[C@H](C)NC(=O)[C@@H](NC(=O)[C@H](CC(C)C)NC(=O)[C@@H](N)CCSC)C(C)C)[C@@H](C)CC)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](C)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](C)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](C)C(=O)N[C@@H](CC(C)C)C(=O)N1[C@@H](CCC1)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CO)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(C)C)C(O)=O)C1=CC=C(O)C=C1 ZRKFYGHZFMAOKI-QMGMOQQFSA-N 0.000 title abstract 2
230000002490 cerebral effect Effects 0.000 title 1
201000010099 disease Diseases 0.000 title 1
208000037265 diseases, disorders, signs and symptoms Diseases 0.000 title 1
239000003112 inhibitor Substances 0.000 title 1
150000001875 compounds Chemical class 0.000 abstract 3
208000018152 Cerebral disease Diseases 0.000 abstract 1
208000007536 Thrombosis Diseases 0.000 abstract 1
230000004071 biological effect Effects 0.000 abstract 1
230000002401 inhibitory effect Effects 0.000 abstract 1
210000002569 neuron Anatomy 0.000 abstract 1
239000008194 pharmaceutical composition Substances 0.000 abstract 1

Classifications

- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/22—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against growth factors ; against growth regulators
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
- A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides

Landscapes

Health & Medical Sciences (AREA)
Chemical & Material Sciences (AREA)
Medicinal Chemistry (AREA)
Life Sciences & Earth Sciences (AREA)
General Health & Medical Sciences (AREA)
Organic Chemistry (AREA)
Public Health (AREA)
Engineering & Computer Science (AREA)
Animal Behavior & Ethology (AREA)
Veterinary Medicine (AREA)
Pharmacology & Pharmacy (AREA)
Immunology (AREA)
Bioinformatics & Cheminformatics (AREA)
Mycology (AREA)
Biomedical Technology (AREA)
Microbiology (AREA)
Proteomics, Peptides & Aminoacids (AREA)
Molecular Biology (AREA)
Epidemiology (AREA)
Genetics & Genomics (AREA)
Biophysics (AREA)
Biochemistry (AREA)
Endocrinology (AREA)
Neurology (AREA)
Neurosurgery (AREA)
Chemical Kinetics & Catalysis (AREA)
General Chemical & Material Sciences (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Nitrogen Condensed Heterocyclic Rings (AREA)

AT99946087T 1998-09-03 1999-09-01 Verwendung von tgf-beta inhibitoren zur behandlung von cerebralen krankheiten ATE311901T1 (de)

Applications Claiming Priority (3)

Application Number	Priority Date	Filing Date	Title
EP98116692		1998-09-03
EP99104033		1999-03-16
PCT/EP1999/006433 WO2000013705A1 (en)	1998-09-03	1999-09-01	Use of tgf-beta inhibitors for treating cerebral disorders

Publications (1)

Publication Number	Publication Date
ATE311901T1 true ATE311901T1 (de)	2005-12-15

Family

ID=26149606

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
AT99946087T ATE311901T1 (de)	1998-09-03	1999-09-01	Verwendung von tgf-beta inhibitoren zur behandlung von cerebralen krankheiten

Country Status (7)

Country	Link
EP (1)	EP1109579B1 (de)
AT (1)	ATE311901T1 (de)
AU (1)	AU5857899A (de)
CA (1)	CA2342208A1 (de)
DE (1)	DE69928814T2 (de)
ES (1)	ES2252974T3 (de)
WO (1)	WO2000013705A1 (de)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
AU2001268147B2 (en) *	2000-06-01	2006-05-04	Children's Medical Center Corporation	Methods and compositions for producing a neurosalutary effect in a subject
US6855690B2 (en)	2000-06-01	2005-02-15	Children's Medical Center Corporation	Methods and compositions for treating ocular disorders
US20030028905A1 (en) *	2001-07-31	2003-02-06	Petra Knaus	Mutant forms of the TGF-beta type II receptor which bind all TGF-beta isoforms
RU2386638C2 (ru)	2004-03-31	2010-04-20	Дженентек, Инк.	Гуманизированные анти-тфр-бета-антитела

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
JPS61112018A (ja) *	1984-11-06	1986-05-30	Mitsubishi Chem Ind Ltd	線溶増強剤
AU3943793A (en) *	1992-04-01	1993-11-08	Whittier Institute For Diabetes And Endocrinology, The	Methods of inhibiting or enhancing scar formation in the CNS
US5399487A (en) *	1993-03-04	1995-03-21	Haematologic Technologies, Inc.	6-peptidylamino-1-naphthalenesulfonamides useful as fluorogenic proteolytic enzyme substrates
EP0726948B1 (de) *	1993-10-14	2007-02-28	President And Fellows Of Harvard College	Verfahren zur induzierung und zur erhaltung neuronalen zellen

1999
- 1999-09-01 AT AT99946087T patent/ATE311901T1/de not_active IP Right Cessation
- 1999-09-01 CA CA002342208A patent/CA2342208A1/en not_active Abandoned
- 1999-09-01 EP EP99946087A patent/EP1109579B1/de not_active Expired - Lifetime
- 1999-09-01 WO PCT/EP1999/006433 patent/WO2000013705A1/en active IP Right Grant
- 1999-09-01 ES ES99946087T patent/ES2252974T3/es not_active Expired - Lifetime
- 1999-09-01 DE DE69928814T patent/DE69928814T2/de not_active Expired - Fee Related
- 1999-09-01 AU AU58578/99A patent/AU5857899A/en not_active Abandoned

Also Published As

Publication number	Publication date
WO2000013705A1 (en)	2000-03-16
CA2342208A1 (en)	2000-03-16
AU5857899A (en)	2000-03-27
ES2252974T3 (es)	2006-05-16
DE69928814T2 (de)	2006-08-03
DE69928814D1 (de)	2006-01-12
EP1109579A1 (de)	2001-06-27
EP1109579B1 (de)	2005-12-07

Similar Documents

Publication	Publication Date	Title
DE69805973D1 (de)	2002-07-18	Behandlung von herzrythmusstörungen durch hemmung einer multifunktionalen calcium/calmodulin-abhängigen protein kinase
ATE241358T1 (de)	2003-06-15	Verwendung von cholinesterasehemmer zur behandlung von konzentrationsstörungen
ATE279181T1 (de)	2004-10-15	Verwendung von 5ht-6 antagonisten zur behandlung adhd
DE69822665D1 (de)	2004-04-29	Verwendung von 9-desoxy-2',9-alpha-methano-3-oxa-4,5,6-trinor-3,7-(1',3'-interphenylen)-13,14-dihydroprostaglandin-f1 zur behandlung von peripheren vaskulären erkrankungen
ATE555803T1 (de)	2012-05-15	Verwendung von osteopontin zur behandlung und/oder vorbeugung von neurologischen erkrankungen
WO2000061167A3 (en)	2001-01-11	TREATMENT OF MYELOMA BONE DISEASE WITH PROTEASOMAL AND NF-λB ACTIVITY INHIBITORS
DE69906671D1 (de)	2003-05-15	Substituierte 2-Phenyl-1-(3,4-dihydroxy-5-nitrophenyl)-1-ethanone, deren Verwendung zur Behandlung von Erkrankungen des zentralen und periphären Nervensystems und diese enthaltende pharmazeutische Zusammensetzungen
ATE554169T1 (de)	2012-05-15	Smad7-inhibitoren zur behandlung von krankheiten des zns
DE60027732D1 (de)	2006-06-08	Verwendung von anti-rubeola antkörpern zur behandlung von symptomen von erkrankungen des zentralen nervensystems
ATE321548T1 (de)	2006-04-15	Verwendung von statin zur behandlung von hauterkrankungen
ATE238792T1 (de)	2003-05-15	Verwendung von makroliden zur behandlung von glaukom
ATE311853T1 (de)	2005-12-15	Verwendung von krillenzymen zur behandlung von zahnbelag
ATE260653T1 (de)	2004-03-15	Verwendung von naaladase inhibitoren zur behandlung von angstzuständen und gedächtnisstörungen
ATE356995T1 (de)	2007-04-15	Verfahren zur identifizierung von mitteln zur behandlung von diabetes
DE60018704D1 (de)	2005-04-21	Bretyliumhaltige zusammensetzungen und kits und deren verwendung zur vorbeugung und behandlung cardiovaskulärer erkrankungen
ATE217191T1 (de)	2002-05-15	Verwendung von phanquinon zur behandlung von alzheimer's krankheit
ATE298246T1 (de)	2005-07-15	Aktiviertes protein c zur behandlung von pankreatitis
ATE225171T1 (de)	2002-10-15	Aminosäurederivate zur behandlung von schlaganfall
ATE313561T1 (de)	2006-01-15	Vgf polypeptide und verfahren zur behandlung von vgf-erkrankungen
ATE266027T1 (de)	2004-05-15	Optisch aktives pyridyl-4h-1,2,4-oxadiazinderivat und seine verwendung zur behandlung von gefässkrankheiten
ATE311901T1 (de)	2005-12-15	Verwendung von tgf-beta inhibitoren zur behandlung von cerebralen krankheiten
DE60108130D1 (de)	2005-02-03	Pharmazeutische zusammensetzungen zur behandlung von neurologischen krankheiten
DE50103012D1 (de)	2004-09-02	Verwendung von hyaluronidase zur prophylaxe und behandlung von herz-kreislauf-erkrankungen
ATE265225T1 (de)	2004-05-15	Pharmazeutische präparation, enthaltend einen rezeptor-antagonisten zur behandlung von blutgerinnungsstörungen
DE60034110D1 (de)	2007-05-10	Verwendung von 4-aminopyridin zur behandlung von peripheren neuropathien

Legal Events

Date	Code	Title	Description
2006-06-15	RER	Ceased as to paragraph 5 lit. 3 law introducing patent treaties